Clinical trials: Cholangiocarcinomas
Cholangiocarcinoma, Biliary Stricture
Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures
This study aims to evaluate the usefulness of disposable digital single-operator cholangioscopy (SOC) and intraductal ultrasound (IDUS) for the accurate diagnosis of indeterminate biliary stricture.
- Trial name
- Spy+IDUS (NCT06369896)
- Volunteers
- 36 people
- Sponsor
- Soonchunhyang University Hospital
Advanced Solid Tumors, NSCLC Adenocarcinoma
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined).
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
- Trial name
- NCT06723236
- Testing
- MGC028
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- MacroGenics
Small Bowel Cancer, Colorectal Cancer
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective.
- Conditions
- Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer
- Trial name
- LIVELONG (NCT06101277)
- Testing
- Ablative local therapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of California, Davis
Biliary Tract Carcinoma
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
This is a study of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma.
- Trial name
- KEYNOTE-966 (NCT04003636)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 185 sites in United States, Argentina and 22 more
- Volunteers
- 1,069 people
- Sponsor
- Merck Sharp & Dohme LLC
Cholangitis
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma
The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar…
- Trial name
- NCT03104569
- Testing
- Injection of 37℃ contrast agent
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- NCT00266097
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cholangiocarcinoma Non-resectable
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for…
- Trial name
- CCGLC-013 (NCT06192797)
- Testing
- HAIC, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Biliary Tract Cancer
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
The purpose of this research study is to determine the safety and efficacy of CPI-613 (devimistat) in the treatment of advanced biliary tract cancer when used in combination with standard of care chemotherapy (gemcitabine plus…
- Trial name
- NCT04203160
- Testing
- CPI 613, Gemcitabine, Cisplatin
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Intrahepatic Cholangiocarcinoma (Icc)
HAIC Plus Systemic Chemotherapy, Lenvatinib and Toripalimab in Advanced ICC
Prognosis for unresectable intrahepatic cholangiocarcinoma (ICC) remains poor. Treatment combination known as Gemox (systemic chemotherapy of gemcitabine and oxaliplatin), along with lenvatinib and toripalimab, has shown favor…
- Trial name
- NCT07304388
- Testing
- hepatic arterial infusion chemotherapy (HAIC), Chemotherapy
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Sun Yat-sen University
Advanced Cholangiocarcinoma (Part 1)
A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping
This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.
- Trial name
- NCT07164703
- Testing
- Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Mao-Lin Yan
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cholangiocarcinoma, Perihilar, Surgery
Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy and the second most common primary hepatic malignancy. The prognosis of CCA is dismal.
- Trial name
- NCT03383796
- Testing
- Three dimensional laparoscopic resection for pCCA, Open resection for pCCA
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7
TAS-102 in Treating Advanced Biliary Tract Cancers
This phase II trial studies how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) works in treating participants with biliary tract cancers that have spread to other places in the body.
- Conditions
- Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7
- Trial name
- NCT03278106
- Testing
- Laboratory Biomarker Analysis, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Hepatocellular Carcinoma, Hepatocellular Cancer
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis
- Trial name
- NCT05064553
- Testing
- Study CT/MRI Imaging, Standard of Care CT/MRI Imaging, Oncoguard™ Liver Test
- Where
- 76 sites in United States
- Volunteers
- 2,990 people
- Sponsor
- Exact Sciences Corporation
Cancer of Liver
Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma
Our long-term working hypothesis is that if 3-D radiation is combined with the effect of capecitabine one hopes to see improved and durable tumor response and survival with acceptable toxicity.
- Trial name
- NCT00216437
- Testing
- Capecitabine (Xeloda)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- James A. Haley Veterans Administration Hospital
Advanced Intrahepatic Cholangiocarcinoma
Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC
This study is a randomized, controlled, open-label, single center clinical study. This study is designed to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Combined With GC versus Sintilimab Combined With GC as…
- Trial name
- ITUS (NCT07152769)
- Testing
- Iparomlimab and Tuvonralimab + GC, Sintilimab + GC
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Pancreatic Cancer, Cholangiocarcinoma
Association Between Cell-free Nucleic Acid in Blood, Urine and Microbiome in Stool With Pancreatobiliary Cancer
Based on the cell free nucleic acid analysis information of blood samples, the results of microbiome and metabolite analysis of stool and urine samples of pancreatic cancer and bile duct cancer patients, the clinical correlations…
- Conditions
- Pancreatic Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT05596370
- Testing
- cell free DNA in blood and urine, metabolite/microbiome in urine and stool
- Where
- 2 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Pancreatic Cancer, Bile Duct Cancer
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
The Comparison of Miniinvasive and Open Pancreaticoduodenectomy for Cancer Pancreaticobiliary Zone
- Conditions
- Pancreatic Cancer, Bile Duct Cancer, Ampulla of Vater Cancer
- Trial name
- NCT04763642
- Testing
- pancreaticoduodenectomy
- Where
- Russia
- Volunteers
- 320 people
- Sponsor
- State Budget Public Health Institution Scientific Research Institute - Ochapovsky Regional Clinical Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.